Table 4.
Pharmaceutical expenditure by type of intravenous antineoplastic drug in the period 2010–2019 in the clinical trial setting.
| Study Year | Cytotoxic Drugs |
Immunotherapy | Targeted Therapy |
Total Expenditure |
Change vs. Previous Year, % |
|---|---|---|---|---|---|
| 2010 | EUR 506,138 | -EUR | EUR 1,951,712 | EUR 2,457,850 | |
| 2011 | EUR 599,725 | -EUR | EUR 1,100,526 | EUR 1,700,250 | −30.8% |
| 2012 | EUR 860,070 | -EUR | EUR 1,343,563 | EUR 2,203,633 | 29.6 |
| 2013 | EUR 863,237 | EUR 590,250 | EUR 1,848,425 | EUR 3,331,912 | 51.2 |
| 2014 | EUR 568,777 | EUR 1,517,637 | EUR 2,550,076 | EUR 4,636,490 | 39.1 |
| 2015 | EUR 787,984 | EUR 222,342 | EUR 3,110,270 | EUR 4,120,596 | −11.1 |
| 2016 | EUR 866,817 | EUR 2,536,316 | EUR 2,817,187 | EUR 6,220,320 | 51.0 |
| 2017 | EUR 1,047,329 | EUR 6,900,964 | EUR 4,727,621 | EUR 12,675,915 | 103.8 |
| 2018 | EUR 940,547 | EUR 12,169,256 | EUR 4,734,946 | EUR 17,844,749 | 40.8 |
| 2019 | EUR 1,217,591 | EUR 11,687,195 | EUR 4,169,878 | EUR 17,074,664 | −4.3 |